Neuroendocrine Tumors
Information
- Disease name
- Neuroendocrine Tumors
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02743741 | Active, not recruiting | N/A | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | July 15, 2016 | June 2026 |
| NCT05013957 | Active, not recruiting | Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study | January 1, 2022 | November 30, 2024 | |
| NCT02174549 | Active, not recruiting | Phase 1/Phase 2 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | September 2014 | December 31, 2025 |
| NCT03980925 | Active, not recruiting | Phase 2 | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | October 11, 2019 | December 2023 |
| NCT04969887 | Active, not recruiting | Phase 2 | Combination Immunotherapy in Rare Cancers Under InvesTigation | August 3, 2021 | March 2028 |
| NCT03910660 | Active, not recruiting | Phase 1/Phase 2 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | February 12, 2019 | December 2025 |
| NCT04804371 | Active, not recruiting | N/A | Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors | March 4, 2021 | February 22, 2025 |
| NCT06148636 | Active, not recruiting | Early Phase 1 | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | November 10, 2023 | November 20, 2027 |
| NCT05249114 | Active, not recruiting | Phase 1 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | December 28, 2022 | December 1, 2026 |
| NCT03728361 | Active, not recruiting | Phase 2 | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | December 31, 2018 | December 31, 2024 |
| NCT02348749 | Active, not recruiting | Phase 1/Phase 2 | 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies | January 2015 | January 2025 |
| NCT05199272 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | December 29, 2021 | March 2025 |
| NCT03691064 | Active, not recruiting | Post-Authorization Long-Term Safety Study of LUTATHERA | November 28, 2018 | June 30, 2028 | |
| NCT03600233 | Active, not recruiting | Phase 2 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | December 15, 2018 | December 31, 2024 |
| NCT03335670 | Active, not recruiting | Early Phase 1 | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors | November 3, 2017 | December 31, 2027 |
| NCT04579757 | Active, not recruiting | Phase 1/Phase 2 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | March 5, 2021 | June 30, 2024 |
| NCT05693519 | Active, not recruiting | GastroIntestinal Cancer in Children and Adolescents | December 22, 2022 | June 22, 2023 | |
| NCT03290079 | Active, not recruiting | Phase 2 | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | December 15, 2017 | July 2024 |
| NCT02489604 | Active, not recruiting | Phase 2 | Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors | December 2013 | December 2023 |
| NCT04544098 | Active, not recruiting | Early Phase 1 | Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver | September 2, 2020 | September 2025 |
| NCT04438304 | Active, not recruiting | Phase 2 | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | March 2, 2021 | October 2024 |
| NCT06356467 | Active, not recruiting | Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs | November 21, 2023 | December 31, 2024 | |
| NCT02568267 | Active, not recruiting | Phase 2 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | November 19, 2015 | April 1, 2025 |
| NCT04375267 | Active, not recruiting | Phase 1 | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours | April 23, 2020 | June 30, 2024 |
| NCT05168631 | Active, not recruiting | Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors | May 16, 2020 | July 1, 2024 | |
| NCT05153772 | Active, not recruiting | Phase 2 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | December 21, 2021 | October 2026 |
| NCT03049189 | Active, not recruiting | Phase 3 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | February 2, 2017 | December 2029 |
| NCT05387603 | Active, not recruiting | Phase 3 | Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. | November 1, 2022 | October 2025 |
| NCT05017662 | Active, not recruiting | N/A | A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 | September 14, 2021 | April 1, 2025 |
| NCT03022188 | Active, not recruiting | Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma | January 10, 2017 | December 2026 | |
| NCT05477576 | Active, not recruiting | Phase 3 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | March 24, 2022 | July 2028 |
| NCT05077384 | Active, not recruiting | Phase 1/Phase 2 | Open-label Study of Surufatinib in Japanese Patients | September 2, 2021 | December 2024 |
| NCT04334837 | Approved for marketing | Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) | |||
| NCT02705313 | Approved for marketing | EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx | |||
| NCT01595009 | Completed | Phase 4 | An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) | April 27, 2011 | August 9, 2016 |
| NCT01619865 | Completed | Phase 1/Phase 2 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | February 21, 2012 | August 27, 2017 |
| NCT01678664 | Completed | Phase 2 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | October 2012 | April 2019 |
| NCT01730417 | Completed | Phase 1 | Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG | November 2009 | July 2011 |
| NCT01794793 | Completed | Phase 4 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | June 10, 2013 | July 29, 2023 |
| NCT01967537 | Completed | Phase 2 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | October 18, 2013 | March 12, 2018 |
| NCT01970540 | Completed | Phase 1 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | May 25, 2011 | August 9, 2017 |
| NCT02067988 | Completed | Phase 2 | Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study | February 2014 | September 1, 2019 |
| NCT02102893 | Completed | Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan | February 13, 2014 | April 15, 2020 | |
| NCT02125474 | Completed | N/A | Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate | November 2013 | October 1, 2019 |
| NCT02132468 | Completed | Phase 2 | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | September 2014 | August 2016 |
| NCT02134639 | Completed | PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation | September 2014 | January 2015 | |
| NCT02246127 | Completed | Phase 3 | Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) | October 27, 2014 | July 12, 2021 |
| NCT02267967 | Completed | Phase 1 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | October 31, 2014 | August 23, 2017 |
| NCT02279602 | Completed | Phase 2 | Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study | December 2014 | August 2016 |
| NCT02299089 | Completed | Phase 2 | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | January 2015 | June 2016 |
| NCT02355535 | Completed | Phase 1 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | February 2015 | May 18, 2020 |
| NCT02402062 | Completed | Phase 2 | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | May 11, 2015 | January 10, 2020 |
| NCT02441062 | Completed | Phase 2 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | September 2015 | January 20, 2020 |
| NCT02489903 | Completed | Phase 2 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | June 2015 | December 6, 2021 |
| NCT02507908 | Completed | 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor' | July 2015 | May 2017 | |
| NCT02539433 | Completed | N/A | Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) | December 2003 | May 2015 |
| NCT02586844 | Completed | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors | October 2013 | April 2021 | |
| NCT02588170 | Completed | Phase 3 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | December 7, 2015 | July 7, 2022 |
| NCT02589821 | Completed | Phase 3 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | December 7, 2015 | July 7, 2022 |
| NCT02609737 | Completed | N/A | Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors | November 13, 2015 | December 10, 2020 |
| NCT02646644 | Completed | Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis | January 2016 | May 2017 | |
| NCT02678780 | Completed | Phase 2 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors | October 2015 | August 2020 |
| NCT02691078 | Completed | Phase 2 | Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors | July 2016 | January 10, 2018 |
| NCT06456723 | Completed | Phase 1/Phase 2 | Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours. | May 14, 2014 | October 17, 2018 |
| NCT00050349 | Completed | Phase 2 | EPO906 in Carcinoid and Other Neuroendocrine Tumors | July 2002 | April 2007 |
| NCT00056693 | Completed | Phase 2 | Treatment With SU11248 in Patients With Neuroendocrine Tumors | April 2003 | September 2006 |
| NCT00137774 | Completed | Phase 2 | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | November 2004 | December 2012 |
| NCT00171873 | Completed | Phase 3 | Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | September 2001 | December 2013 |
| NCT00398320 | Completed | Phase 2 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | November 2006 | October 2012 |
| NCT00424723 | Completed | Phase 2 | Pemetrexed in Patients With Advanced Neuroendocrine Tumors | December 2005 | March 2010 |
| NCT00442533 | Completed | Phase 2/Phase 3 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | August 2005 | December 28, 2015 |
| NCT00501540 | Completed | Phase 2 | Lithium for Low-Grade Neuroendocrine Tumors | July 2007 | June 2009 |
| NCT00605566 | Completed | Phase 2 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | January 2008 | February 2015 |
| NCT00610129 | Completed | Phase 2 | Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) | January 2008 | January 2010 |
| NCT00747786 | Completed | Non Interventional Post Marketing Programme in Neuroendocrine Tumours | December 2008 | August 2013 | |
| NCT00780663 | Completed | Phase 2 | Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | October 2008 | March 2010 |
| NCT00781911 | Completed | Phase 2 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | February 2009 | May 2016 |
| NCT00815620 | Completed | Best Therapy for Patients With Neuroendocrine Tumors | November 2008 | March 2017 | |
| NCT00869050 | Completed | Phase 2 | Capecitabine and Temozolomide for Neuroendocrine Cancers | August 2005 | October 2014 |
| NCT00953394 | Completed | Phase 2 | 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | February 2002 | December 2006 |
| NCT00978211 | Completed | Phase 2 | DOTA-TOC in Metastasized Neuroendocrine Tumors | September 1997 | December 2013 |
| NCT01099228 | Completed | N/A | Combination Targeted Radiotherapy in Neuroendocrine Tumors | September 2006 | July 2015 |
| NCT01135849 | Completed | B-Receptor Signaling in Cardiomyopathy | November 2008 | October 2010 | |
| NCT01218555 | Completed | Phase 1 | Study of Everolimus (RAD001) in Combination With Lenalidomide | September 9, 2010 | November 5, 2020 |
| NCT01234168 | Completed | A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea | October 2010 | December 2012 | |
| NCT01237457 | Completed | Phase 2 | 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms | October 27, 2010 | July 25, 2017 |
| NCT01253161 | Completed | Phase 2 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | February 1, 2011 | March 2, 2023 |
| NCT01262235 | Completed | Phase 1/Phase 2 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | December 2010 | August 2015 |
| NCT01290536 | Completed | Phase 2 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | May 2010 | October 2013 |
| NCT01317615 | Completed | Phase 4 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | April 2011 | March 2015 |
| NCT01338090 | Completed | 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors | April 2010 | March 2012 | |
| NCT01364415 | Completed | Phase 1 | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | August 2011 | April 2016 |
| NCT01398306 | Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | July 2011 | April 2012 | |
| NCT01456078 | Completed | Phase 2 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors | October 2011 | November 2018 |
| NCT01469572 | Completed | Phase 1 | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | December 2011 | October 2018 |
| NCT01524783 | Completed | Phase 3 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | March 30, 2012 | August 7, 2020 |
| NCT01590199 | Completed | Phase 1 | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs | May 18, 2012 | September 11, 2018 |
| NCT02810600 | Completed | Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors | June 8, 2016 | May 29, 2020 | |
| NCT02815969 | Completed | The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors | September 2016 | August 2019 | |
| NCT02838342 | Completed | Phase 2 | Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors | May 19, 2015 | June 29, 2021 |
| NCT02840149 | Completed | Phase 3 | SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors | October 1, 2019 | December 13, 2023 |
| NCT02936323 | Completed | Phase 1/Phase 2 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | December 8, 2016 | February 25, 2021 |
| NCT02939651 | Completed | Phase 2 | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | October 26, 2016 | March 2020 |
| NCT02973204 | Completed | Circulating Tumor Cells and Tumor DNA in HCC and NET | November 2016 | January 8, 2020 | |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT03042416 | Completed | Phase 3 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | June 29, 2017 | June 2, 2021 |
| NCT03070301 | Completed | Phase 2 | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | February 27, 2017 | January 31, 2024 |
| NCT03079440 | Completed | Phase 2 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | May 15, 2017 | November 15, 2022 |
| NCT03095274 | Completed | Phase 2 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin | April 11, 2017 | May 23, 2022 |
| NCT03112694 | Completed | Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors | April 4, 2017 | November 2, 2017 | |
| NCT03136328 | Completed | Phase 3 | Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan | May 16, 2016 | March 2017 |
| NCT03167853 | Completed | Phase 1 | Study of JS001 in Patients With Advanced Neuroendocrine Tumors | April 6, 2017 | May 11, 2019 |
| NCT03183271 | Completed | N/A | Proton Boost for Locally Advanced HEAD AND NECK TUMORS | July 16, 2012 | September 30, 2016 |
| NCT03217097 | Completed | N/A | MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents | October 16, 2018 | April 25, 2022 |
| NCT03220087 | Completed | Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain | July 21, 2017 | April 30, 2018 | |
| NCT03271281 | Completed | Phase 2 | PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 | December 4, 2017 | December 31, 2021 |
| NCT03273712 | Completed | Phase 2 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | September 29, 2017 | May 27, 2020 |
| NCT03278275 | Completed | Phase 2 | PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 | November 1, 2017 | July 8, 2021 |
| NCT03289741 | Completed | Phase 4 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | September 19, 2017 | April 10, 2023 |
| NCT03562091 | Completed | Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel | July 20, 2018 | May 15, 2020 | |
| NCT03590119 | Completed | Phase 2/Phase 3 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases | August 1, 2018 | September 1, 2022 |
| NCT03673943 | Completed | Phase 3 | Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE | August 23, 2018 | August 7, 2019 |
| NCT03722511 | Completed | Phase 2 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | December 6, 2018 | May 18, 2021 |
| NCT03834701 | Completed | N/A | Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms | September 1, 2019 | February 1, 2024 |
| NCT03840720 | Completed | The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET | February 1, 2019 | December 31, 2019 | |
| NCT03870399 | Completed | Phase 2 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | March 13, 2019 | May 13, 2023 |
| NCT03873870 | Completed | N/A | 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors | March 28, 2019 | April 30, 2023 |
| NCT03883776 | Completed | Phase 1 | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors | April 11, 2019 | October 29, 2019 |
| NCT03948841 | Completed | Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences | January 1, 2011 | September 1, 2016 | |
| NCT04129255 | Completed | Phase 2 | Octreotide LAR in the Induction of Immunologic Response in NENs Patients | June 28, 2017 | December 1, 2019 |
| NCT04197310 | Completed | Phase 2 | Cabozantinib and Nivolumab for Carcinoid Tumors | December 26, 2019 | January 31, 2024 |
| NCT04207762 | Completed | 18F-AmBF3-TATE PET/CT for Imaging NET Patients | June 9, 2020 | January 15, 2021 | |
| NCT04296149 | Completed | Phase 2 | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe | February 16, 2017 | December 31, 2019 |
| NCT04318561 | Completed | Phase 1/Phase 2 | Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors | December 1, 2019 | December 1, 2021 |
| NCT04365023 | Completed | Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors | July 2, 2020 | May 25, 2023 | |
| NCT04385992 | Completed | Phase 2 | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET | March 9, 2020 | June 26, 2023 |
| NCT04440956 | Completed | Early Phase 1 | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours | May 21, 2015 | February 25, 2016 |
| NCT04476082 | Completed | Nutrition in Gastrointestinal Tumors | June 25, 2020 | December 6, 2022 | |
| NCT04552847 | Completed | Phase 2/Phase 3 | Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors | October 7, 2020 | February 8, 2022 |
| NCT04753229 | Completed | Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia | January 1, 2008 | October 1, 2020 | |
| NCT04780737 | Completed | Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis | January 2000 | July 2020 | |
| NCT04922801 | Completed | Optimising Molecular Radionuclide Therapy | December 9, 2021 | November 5, 2022 | |
| NCT05255133 | Completed | N/A | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment | October 9, 2017 | June 23, 2022 |
| NCT05427032 | Completed | HRQoL During PRRT in Patients With NETs | January 10, 2009 | December 10, 2018 | |
| NCT05565066 | Completed | A Real-world Comparison of FNB and FNA in IHC-required Lesions. | December 1, 2014 | October 31, 2022 | |
| NCT05680675 | Completed | N/A | Dual-Tracer Theranostic PET | December 8, 2022 | June 4, 2024 |
| NCT05871320 | Completed | Early Phase 1 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms | December 23, 2022 | June 30, 2023 |
| NCT06143605 | Completed | Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors | January 30, 2013 | September 30, 2023 | |
| NCT06155994 | Completed | Phase 1/Phase 2 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | January 20, 2021 | June 30, 2023 |
| NCT06211803 | Completed | Clinical Application of the Prototype J-PET Device | March 11, 2022 | March 22, 2022 | |
| NCT00037869 | Completed | Phase 3 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | November 2001 | January 2005 |
| NCT05064150 | Enrolling by invitation | Neuroendocrine Tumors - Patient Reported Outcomes | May 10, 2022 | June 2026 | |
| NCT05709171 | Enrolling by invitation | Phase 2 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | January 17, 2023 | January 1, 2026 |
| NCT05396118 | Enrolling by invitation | Phase 2 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | May 18, 2022 | December 2024 |
| NCT00923026 | Enrolling by invitation | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | June 15, 2009 | ||
| NCT05160480 | Enrolling by invitation | N/A | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | June 2024 | March 1, 2026 |
| NCT02174679 | No longer available | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | |||
| NCT02375464 | No longer available | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | April 2015 | December 2019 | |
| NCT02358018 | No longer available | 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial | |||
| NCT04814732 | No longer available | Expanded Access Program of Surufatinib | |||
| NCT04889742 | Not yet recruiting | Phase 2 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors | May 10, 2024 | January 2028 |
| NCT05894486 | Not yet recruiting | Phase 2 | Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors | June 5, 2023 | June 5, 2026 |
| NCT06345079 | Not yet recruiting | Phase 2 | Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | July 2024 | June 2028 |
| NCT06122610 | Not yet recruiting | Phase 1 | Using Novel Imaging to More Safely Treat Neuroendocrine Tumors | June 2024 | March 2025 |
| NCT04432532 | Not yet recruiting | Neuroendocrine and Adrenal Tumors | May 1, 2024 | March 1, 2025 | |
| NCT06455358 | Not yet recruiting | Phase 1/Phase 2 | 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) | June 2024 | June 2028 |
| NCT05987176 | Not yet recruiting | Phase 2 | Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases | November 1, 2023 | December 30, 2028 |
| NCT06045260 | Not yet recruiting | Phase 2 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC | October 2023 | January 2027 |
| NCT05967481 | Not yet recruiting | Evaluation of Study Experiences of Neuroendocrine Tumor Patients | August 2024 | August 2026 | |
| NCT06395402 | Not yet recruiting | Phase 2 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry | May 1, 2024 | March 17, 2029 |
| NCT04788927 | Not yet recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study | October 1, 2023 | September 30, 2027 | |
| NCT06300216 | Not yet recruiting | A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors | March 26, 2024 | May 26, 2028 | |
| NCT06358001 | Not yet recruiting | EchoTip AcuCore Post-Market Clinical Study | June 1, 2024 | June 1, 2025 | |
| NCT06038461 | Not yet recruiting | Phase 1/Phase 2 | An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors | September 15, 2023 | September 15, 2026 |
| NCT06263088 | Not yet recruiting | N/A | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | July 2024 | June 30, 2026 |
| NCT06232564 | Not yet recruiting | Phase 2 | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs | March 2, 2024 | August 2, 2028 |
| NCT03206060 | Recruiting | Phase 2 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | October 10, 2017 | January 1, 2027 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT05997056 | Recruiting | Phase 2 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | November 7, 2023 | December 8, 2025 |
| NCT06015802 | Recruiting | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors | April 1, 2021 | March 2029 | |
| NCT06041516 | Recruiting | Phase 1 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | June 23, 2024 | October 30, 2029 |
| NCT06055439 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | May 2024 | May 2027 |
| NCT06056362 | Recruiting | Phase 1/Phase 2 | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors | March 23, 2023 | March 23, 2025 |
| NCT03935893 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | December 3, 2019 | June 30, 2037 |
| NCT06121752 | Recruiting | N/A | Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors | November 10, 2023 | October 30, 2024 |
| NCT04017104 | Recruiting | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | November 1, 2019 | August 1, 2024 | |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04045834 | Recruiting | Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia | May 5, 2019 | December 31, 2023 | |
| NCT04066322 | Recruiting | Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment | August 25, 2019 | July 25, 2025 | |
| NCT04074135 | Recruiting | Phase 2 | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | June 2, 2020 | July 1, 2036 |
| NCT04086485 | Recruiting | Phase 1/Phase 2 | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | October 3, 2022 | January 1, 2026 |
| NCT04090034 | Recruiting | Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors | March 28, 2024 | June 28, 2024 | |
| NCT04104529 | Recruiting | N/A | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department | October 28, 2019 | October 2026 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT04166006 | Recruiting | Phase 2 | A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. | December 12, 2019 | December 2026 |
| NCT06430021 | Recruiting | Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation | June 13, 2024 | June 2025 | |
| NCT04291885 | Recruiting | Phase 2 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | October 26, 2020 | April 1, 2028 |
| NCT06448208 | Recruiting | Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors | June 3, 2024 | June 2026 | |
| NCT06159920 | Recruiting | Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. | October 27, 2021 | December 27, 2024 | |
| NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
| NCT04339036 | Recruiting | Phase 2 | CapTemY90 for Grade 2 NET Liver Metastases | October 7, 2021 | May 1, 2026 |
| NCT04362436 | Recruiting | Phase 2 | TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets | January 24, 2019 | September 30, 2024 |
| NCT06204159 | Recruiting | N/A | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery | February 1, 2024 | June 30, 2026 |
| NCT04444401 | Recruiting | Registry on NEN Patients and COVID-19 | June 15, 2020 | December 15, 2023 | |
| NCT04464122 | Recruiting | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) | September 14, 2020 | December 31, 2024 | |
| NCT06242119 | Recruiting | Clinical Application of the J-PET Scanner Prototype | March 7, 2024 | October 14, 2024 | |
| NCT04510311 | Recruiting | Early Phase 1 | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors | October 19, 2020 | April 2024 |
| NCT04524208 | Recruiting | Phase 2 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 | March 1, 2021 | October 31, 2024 |
| NCT04584008 | Recruiting | N/A | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | September 23, 2020 | February 2024 |
| NCT04696042 | Recruiting | Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs | January 1, 2021 | January 30, 2025 | |
| NCT04706910 | Recruiting | Phase 3 | 18F-DOPA II - PET Imaging Optimization | January 20, 2021 | July 2026 |
| NCT06321692 | Recruiting | N/A | Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications | October 9, 2019 | December 31, 2024 |
| NCT04847505 | Recruiting | Phase 3 | 68Ga-DOTA-TATE PET/CT Imaging in NETs | January 1, 2020 | December 31, 2025 |
| NCT04848337 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | May 25, 2021 | July 2024 |
| NCT04888481 | Recruiting | Phase 2 | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors | February 15, 2022 | August 31, 2028 |
| NCT04893759 | Recruiting | Phase 1 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | January 6, 2022 | June 1, 2025 |
| NCT04897542 | Recruiting | Early Phase 1 | Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors | December 1, 2020 | December 1, 2023 |
| NCT04919226 | Recruiting | Phase 3 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | December 21, 2021 | September 2027 |
| NCT06344507 | Recruiting | Iconographic Registry of Pancreatobiliary Endoscopy Procedures | March 28, 2022 | December 31, 2027 | |
| NCT04949282 | Recruiting | Spanish Series of Patients Treated With the Radionuclide Lutetium177 | May 10, 2021 | December 31, 2035 | |
| NCT04954820 | Recruiting | Phase 2 | Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | October 18, 2021 | September 2029 |
| NCT05000294 | Recruiting | Phase 1/Phase 2 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | December 7, 2021 | December 2025 |
| NCT05053854 | Recruiting | Phase 1 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | December 8, 2021 | December 31, 2025 |
| NCT05076786 | Recruiting | Phase 2 | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma | October 27, 2021 | October 15, 2024 |
| NCT05113355 | Recruiting | Phase 2 | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm | November 17, 2021 | November 15, 2024 |
| NCT01039922 | Recruiting | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland | January 2008 | January 2028 | |
| NCT05178693 | Recruiting | Phase 1 | Lutathera and ASTX727 in Neuroendocrine Tumours | April 25, 2022 | December 31, 2025 |
| NCT05237934 | Recruiting | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | April 25, 2022 | December 31, 2032 | |
| NCT05255159 | Recruiting | Phase 2 | Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors | October 15, 2022 | December 2024 |
| NCT05268952 | Recruiting | N/A | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) | May 27, 2019 | December 31, 2025 |
| NCT05334290 | Recruiting | Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment | August 6, 2020 | August 5, 2024 | |
| NCT02749331 | Recruiting | Phase 1/Phase 2 | Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy | March 2016 | September 2024 |
| NCT02754297 | Recruiting | Phase 2 | Personalized PRRT of Neuroendocrine Tumors | April 12, 2016 | April 12, 2029 |
| NCT05443087 | Recruiting | N/A | TARGETed Therapy Drug MONITOring in DIGestive Oncology | August 29, 2022 | June 2027 |
| NCT05459844 | Recruiting | Phase 3 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | August 31, 2022 | December 2028 |
| NCT05475210 | Recruiting | Phase 1 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | June 18, 2022 | March 30, 2025 |
| NCT05500391 | Recruiting | Phase 2 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring | February 28, 2024 | October 2029 |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT05513469 | Recruiting | N/A | Biomarker Identification of Radionuclide Therapy-induced Radiation Responses | January 1, 2023 | October 1, 2024 |
| NCT05554003 | Recruiting | Phase 2 | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study | January 14, 2022 | December 31, 2024 |
| NCT05556473 | Recruiting | Phase 1 | F-Tryptophan PET/CT in Human Cancers | September 29, 2022 | December 31, 2024 |
| NCT05636618 | Recruiting | Phase 1/Phase 2 | Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | September 27, 2023 | January 31, 2028 |
| NCT03145857 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | March 5, 2020 | December 2031 |
| NCT05746208 | Recruiting | Phase 2 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | July 17, 2023 | October 31, 2027 |
| NCT05804331 | Recruiting | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study | March 14, 2023 | September 14, 2028 | |
| NCT05870423 | Recruiting | Phase 1 | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors | June 1, 2022 | January 1, 2025 |
| NCT06402695 | Recruiting | Observational Study on GEP-and Pulm-NET Treated at FPG | September 15, 2023 | July 2026 | |
| NCT05918302 | Recruiting | Phase 3 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. | October 27, 2023 | July 2028 |
| NCT03412877 | Recruiting | Phase 2 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | September 6, 2018 | March 23, 2028 |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT03478358 | Recruiting | Phase 1 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | April 30, 2017 | May 1, 2023 |
| NCT00843531 | Terminated | Phase 2 | RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | June 25, 2009 | August 20, 2016 |
| NCT03724409 | Terminated | Early Phase 1 | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases | October 11, 2018 | May 23, 2023 |
| NCT01163526 | Terminated | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | September 2010 | July 2016 | |
| NCT01115803 | Terminated | Phase 1 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | March 2010 | June 2011 |
| NCT00985946 | Terminated | Phase 2 | Study of Panobinostat in Patients With Neuroendocrine Tumors | May 2010 | April 2015 |
| NCT00947167 | Terminated | Phase 2 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | March 2009 | May 2010 |
| NCT03190213 | Terminated | Phase 2 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma | December 4, 2017 | March 11, 2019 |
| NCT03211988 | Terminated | Phase 2 | Entinostat Neuroendocrine (NE) Tumor | December 23, 2017 | December 31, 2021 |
| NCT04258592 | Terminated | Phase 1 | 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors | February 7, 2020 | July 7, 2022 |
| NCT03420521 | Terminated | Phase 2 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | March 9, 2018 | November 24, 2021 |
| NCT00227136 | Terminated | Phase 3 | Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | May 2005 | September 2005 |
| NCT04140409 | Terminated | Phase 4 | Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation | February 2, 2016 | September 19, 2019 |
| NCT01755182 | Terminated | Phase 3 | Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors | July 2013 | March 2016 |
| NCT03670030 | Terminated | Phase 2 | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | November 5, 2018 | February 26, 2021 |
| NCT02359500 | Terminated | Phase 1 | 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) | December 2014 | January 23, 2017 |
| NCT04488263 | Terminated | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | November 24, 2020 | January 11, 2023 | |
| NCT02859064 | Terminated | Phase 2 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | July 28, 2017 | June 10, 2022 |
| NCT04543955 | Terminated | Phase 2 | Telotristat With Lutathera in Neuroendocrine Tumors | September 13, 2021 | June 3, 2022 |
| NCT04077372 | Terminated | N/A | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | September 16, 2019 | October 11, 2020 |
| NCT01719861 | Terminated | Phase 2 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | October 2012 | May 2015 |
| NCT04644315 | Terminated | Phase 2 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | May 24, 2021 | May 16, 2022 |
| NCT02943733 | Terminated | Phase 1 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | August 22, 2017 | January 31, 2022 |
| NCT01215578 | Terminated | Phase 2 | Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | October 2008 | December 2014 |
| NCT03014297 | Terminated | Phase 1 | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | March 6, 2017 | November 16, 2018 |
| NCT03986593 | Terminated | N/A | Cryoablation of Bone Metastases From Endocrine Tumors | September 26, 2019 | May 29, 2023 |
| NCT05922579 | Terminated | A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET | June 15, 2023 | December 1, 2023 | |
| NCT02592707 | Terminated | Phase 1/Phase 2 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | March 6, 2017 | February 22, 2022 |
| NCT02315625 | Terminated | Phase 2 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | April 8, 2015 | May 22, 2019 |
| NCT00851604 | Unknown status | ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors | March 2009 | January 2011 | |
| NCT02736500 | Unknown status | Phase 1/Phase 2 | Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors | September 2, 2015 | June 2021 |
| NCT03083210 | Unknown status | Phase 4 | Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET | July 5, 2017 | February 2020 |
| NCT04331912 | Unknown status | PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment | July 1, 2019 | December 31, 2023 | |
| NCT03422029 | Unknown status | Phase 2 | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | January 31, 2018 | December 30, 2021 |
| NCT04336839 | Unknown status | Portal Vein Resection in Pancreatic Neuroendocrine Tumours | May 1, 2020 | August 31, 2020 | |
| NCT03749681 | Unknown status | Neuroendocrine Tumors of Old Patients in the West of France | December 2018 | March 28, 2020 | |
| NCT03288597 | Unknown status | Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms | September 1, 2017 | September 1, 2020 | |
| NCT02823691 | Unknown status | Early Phase 1 | The MetNET-2 Trial | April 2016 | December 2021 |
| NCT01931488 | Unknown status | Phase 2 | 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. | August 2013 | January 2016 |
| NCT04152928 | Unknown status | N/A | Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities | February 25, 2020 | February 25, 2022 |
| NCT04427787 | Unknown status | Phase 2 | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET | June 20, 2020 | November 2023 |
| NCT02246322 | Unknown status | N/A | A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. | August 2013 | November 2014 |
| NCT03278379 | Unknown status | Phase 2 | Avelumab in G2-3 NET | November 15, 2017 | September 20, 2021 |
| NCT03372356 | Unknown status | Psychosocial Screening for Neuroendocrine Tumor Patients | August 9, 2017 | August 9, 2020 | |
| NCT04622631 | Unknown status | Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT | November 2020 | January 2023 | |
| NCT05246319 | Unknown status | Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors | January 1, 2012 | December 31, 2022 | |
| NCT03881306 | Unknown status | Phase 1/Phase 2 | DEBOXA for Inoperable NET Liver Metastases | July 1, 2018 | December 31, 2021 |
| NCT03576040 | Unknown status | Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors | July 19, 2018 | July 2023 | |
| NCT04154241 | Unknown status | N/A | Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor | March 10, 2020 | March 10, 2022 |
| NCT03288402 | Unknown status | N/A | Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients | January 2017 | January 31, 2020 |
| NCT04194125 | Unknown status | Phase 2 | Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer | February 1, 2019 | January 31, 2022 |
| NCT03454763 | Unknown status | Phase 2 | Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors | May 26, 2016 | May 2021 |
| NCT04041882 | Unknown status | Early Phase 1 | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor | April 1, 2014 | January 30, 2022 |
| NCT04085211 | Unknown status | Image-Enhanced Endoscopy in the Gastrointestinal Tract | July 1, 2019 | May 2022 | |
| NCT03279601 | Unknown status | Phase 2 | Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor | September 1, 2017 | September 1, 2020 |
| NCT02838862 | Unknown status | Identification of Biomarker Profiles GEP-NEN Patients | July 2016 | June 2017 | |
| NCT04790708 | Unknown status | N/A | Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) | July 2, 2018 | June 30, 2023 |
| NCT04491851 | Unknown status | Phase 2 | Impact of Peptides and Chelators on Somatostatin Receptor Antagonists | October 1, 2020 | September 2021 |
| NCT02455596 | Unknown status | Phase 2 | Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors | May 2015 | December 2016 |
| NCT04029428 | Unknown status | Phase 2 | Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression | November 2, 2004 | January 1, 2021 |
| NCT03308682 | Unknown status | Phase 1 | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | April 30, 2017 | May 1, 2018 |
| NCT01201096 | Unknown status | Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) | September 2010 | September 2018 | |
| NCT01744249 | Unknown status | Phase 2/Phase 3 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | November 2011 | October 2021 |
| NCT01175096 | Unknown status | Phase 1/Phase 2 | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | July 2010 | January 2012 |
| NCT03130205 | Unknown status | Biomarker Study in Pancreatic Neuroendocrine Tumours | May 1, 2017 | January 1, 2022 | |
| NCT00687778 | Unknown status | 11C-Acetate PET/CT Non-FDG-Avid Tumors | May 2008 | June 2010 | |
| NCT03629847 | Unknown status | Phase 1/Phase 2 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | December 2012 | December 2018 |
| NCT03689231 | Unknown status | Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs). | March 1, 2018 | December 30, 2018 | |
| NCT04713202 | Withdrawn | Phase 2 | Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl | March 3, 2021 | February 2024 |
| NCT04915144 | Withdrawn | Phase 2 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | January 15, 2023 | December 31, 2031 |
| NCT04614766 | Withdrawn | Phase 1/Phase 2 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors | September 30, 2022 | April 23, 2024 |
| NCT04672876 | Withdrawn | Phase 2 | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors | January 2022 | October 1, 2023 |
| NCT04276597 | Withdrawn | Phase 2 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | March 4, 2020 | July 15, 2021 |
| NCT04034745 | Withdrawn | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | October 2020 | November 2023 | |
| NCT04831567 | Withdrawn | Phase 2 | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors | February 4, 2021 | May 13, 2022 |
| NCT03895463 | Withdrawn | Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice | August 2019 | March 26, 2023 | |
| NCT03923257 | Withdrawn | Phase 1/Phase 2 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | August 4, 2020 | June 3, 2021 |
| NCT02882503 | Withdrawn | N/A | Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors | June 2016 | May 7, 2019 |
| NCT00657332 | Withdrawn | Clinical and Pathologic Studies in Neuroendocrine Tumors | July 2007 | June 17, 2008 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018358